We are live on ! Find out more
CTNM

Contineum Therapeutics
CTNM

49 hedge funds and large institutions have $229M invested in Contineum Therapeutics in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

68.54% more ownership

Funds ownership: 0% → 68.54% (+69%)

Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
0.71%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.04%
New
49
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$33.1M
2
JJ
Johnson & Johnson
New Jersey
+$31.9M
3
PA
Perceptive Advisors
New York
+$25.2M
4
VVM
Versant Venture Management
California
+$14.8M
5
SAM
Sectoral Asset Management
Quebec, Canada
+$12.9M

Top Sellers

No sellers this quarter

CTNM Hedge Fund Activity: Q2 2024 in Review

49 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q2 2024, worth a combined $229M.

Buyers outnumbered sellers: 49 funds opened new CTNM positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $33.1M.

  • 49 institutional investors held Contineum Therapeutics (CTNM) as of Q2 2024, up from 0 in Q1 2024.
  • Funds reported $229M of Contineum Therapeutics stock for Q2 2024.
  • 49 funds opened new Contineum Therapeutics positions in Q2 2024 and 0 closed out, a net change of +49 holders.
  • The largest Contineum Therapeutics buyer in Q2 2024 was Suvretta Capital Management, an estimated $33.1M added.

Based on aggregated 13F filings for Q2 2024.